Novo Nordisk Analyst Price Targets

Novo Nordisk AS

NVONYSE

$46.77

1.653.66%

al cierre: Sep 2, 5:00 PM EST

$46.73

-0.04-0.09%

After hour: 7:57 PM EST

Wall Street analyst price targets and consensus rating for Novo Nordisk (NVO).

Price Target Range — 9 Quarters

Analyst Consensus — 12 Analysts

4Buy

6Hold

2Sell

Consensus RatingOverweight# Analysts12Avg. Consensus PT$85Upside to Avg. PT+82.6%

Rating Trend — Last 9 Months

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 2, 2026	Goldman Sachs	James Quigley	Downgrade	Buy→Neutral	$63→$41
Feb 24, 2026	JP Morgan	Richard Vosser	Downgrade	Overweight→Neutral	—
Jan 9, 2026	CICC	—	Initiate	Outperform	$74
Dec 8, 2025	Argus Research	John Eade	Downgrade	Buy→Hold	—
Nov 28, 2025	Goldman Sachs	James Quigley	PT Cut	Buy	$60→$54
Nov 25, 2025	BMO Capital	Evan David Seigerman	PT Cut	Market Perform	$50→$46
Nov 24, 2025	HSBC	Rajesh Kumar	Downgrade	Buy→Hold	—
Oct 27, 2025	Jefferies	Michael Leuchten	Assumes	Underperform	—
Oct 14, 2025	BMO Capital	Evan David Seigerman	PT Raise	Market Perform	$50→$55
Oct 2, 2025	HSBC	Rajesh Kumar	Upgrade	Hold→Buy	$70
Sep 29, 2025	Morgan Stanley	Thibault Boutherin	Downgrade	Equal-Weight→Underweight	$59→$47
Sep 17, 2025	Berenberg	Kerry Holford	Upgrade	Hold→Buy	—
Aug 19, 2025	TD Cowen	Michael Nedelcovych	PT Cut	Buy	$105→$70
Aug 5, 2025	UBS	Matthew Weston	Downgrade	Buy→Neutral	—
Jul 31, 2025	HSBC	Rajesh Kumar	Downgrade	Buy→Hold	—
Jul 30, 2025	Barclays	Emily Field	Downgrade	Overweight→Equal-Weight	—
Jun 18, 2025	TD Cowen	Michael Nedelcovych	Maintained	Buy	$105
Apr 17, 2025	BMO Capital	Evan David Seigerman	Downgrade	Outperform→Market Perform	$105→$64
Jan 8, 2025	UBS	Jo Walton	Upgrade	Sell→Buy	—
Dec 23, 2024	BMO Capital	Evan David Seigerman	PT Cut	Outperform	$156→$105